Literature DB >> 20397150

Estimating gene penetrance from family data.

Gail Gong1, Nathan Hannon, Alice S Whittemore.   

Abstract

Family data are useful for estimating disease risk in carriers of specific genotypes of a given gene (penetrance). Penetrance is frequently estimated assuming that relatives' phenotypes are independent, given their genotypes for the gene of interest. This assumption is unrealistic when multiple shared risk factors contribute to disease risk. In this setting, the phenotypes of relatives are correlated even after adjustment for the genotypes of any one gene (residual correlation). Many methods have been proposed to address this problem, but their performance has not been evaluated systematically. In simulations we generated genotypes for a rare (frequency 0.35%) allele of moderate penetrance, and a common (frequency 15%) allele of low penetrance, and then generated correlated disease survival times using the Clayton-Oakes copula model. We ascertained families using both population and clinic designs. We then compared the estimates of several methods to the optimal ones obtained from the model used to generate the data. We found that penetrance estimates for common low-risk genotypes were more robust to model misspecification than those for rare, moderate-risk genotypes. For the latter, penetrance estimates obtained ignoring residual disease correlation had large biases. Also biased were estimates based only on families that segregate the risk allele. In contrast, a method for accommodating phenotype correlation by assuming the presence of genetic heterogeneity performed nearly optimally, even when the survival data were coded as binary outcomes. We conclude that penetrance estimates that accommodate residual phenotype correlation (even only approximately) outperform those that ignore it, and that coding censored survival outcomes as binary does not substantially increase the mean-square error of the estimates, provided the censoring is not extensive. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20397150      PMCID: PMC3003663          DOI: 10.1002/gepi.20493

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  27 in total

1.  Bias and efficiency in family-based gene-characterization studies: conditional, prospective, retrospective, and joint likelihoods.

Authors:  P Kraft; D C Thomas
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

2.  Evaluation of candidate genes in case-control studies: a statistical method to account for related subjects.

Authors:  S L Slager; D J Schaid
Journal:  Am J Hum Genet       Date:  2001-05-15       Impact factor: 11.025

3.  Optimal designs for estimating penetrance of rare mutations of a disease-susceptibility gene.

Authors:  Gail Gong; Alice S Whittemore
Journal:  Genet Epidemiol       Date:  2003-04       Impact factor: 2.135

4.  Polygenic inheritance of breast cancer: Implications for design of association studies.

Authors:  Antonis C Antoniou; Douglas F Easton
Journal:  Genet Epidemiol       Date:  2003-11       Impact factor: 2.135

5.  Estimating disease risk associated with mutated genes in family-based designs.

Authors:  Yun-Hee Choi; Karen A Kopciuk; Laurent Briollais
Journal:  Hum Hered       Date:  2008-07-09       Impact factor: 0.444

6.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

Authors:  A Antoniou; P D P Pharoah; S Narod; H A Risch; J E Eyfjord; J L Hopper; N Loman; H Olsson; O Johannsson; A Borg; B Pasini; P Radice; S Manoukian; D M Eccles; N Tang; E Olah; H Anton-Culver; E Warner; J Lubinski; J Gronwald; B Gorski; H Tulinius; S Thorlacius; H Eerola; H Nevanlinna; K Syrjäkoski; O-P Kallioniemi; D Thompson; C Evans; J Peto; F Lalloo; D G Evans; D F Easton
Journal:  Am J Hum Genet       Date:  2003-04-03       Impact factor: 11.025

7.  Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.

Authors:  Hanne Meijers-Heijboer; Ans van den Ouweland; Jan Klijn; Marijke Wasielewski; Anja de Snoo; Rogier Oldenburg; Antoinette Hollestelle; Mark Houben; Ellen Crepin; Monique van Veghel-Plandsoen; Fons Elstrodt; Cornelia van Duijn; Carina Bartels; Carel Meijers; Mieke Schutte; Lesley McGuffog; Deborah Thompson; Douglas Easton; Nayanta Sodha; Sheila Seal; Rita Barfoot; Jon Mangion; Jenny Chang-Claude; Diana Eccles; Rosalind Eeles; D Gareth Evans; Richard Houlston; Victoria Murday; Steven Narod; Tamara Peretz; Julian Peto; Catherine Phelan; Hong Xiang Zhang; Csilla Szabo; Peter Devilee; David Goldgar; P Andrew Futreal; Katherine L Nathanson; Barbara Weber; Nazneen Rahman; Michael R Stratton
Journal:  Nat Genet       Date:  2002-04-22       Impact factor: 38.330

8.  Logistic regression of family data from retrospective study designs.

Authors:  Alice S Whittemore; Jerry Halpern
Journal:  Genet Epidemiol       Date:  2003-11       Impact factor: 2.135

9.  On the use of familial aggregation in population-based case probands for calculating penetrance.

Authors:  Colin B Begg
Journal:  J Natl Cancer Inst       Date:  2002-08-21       Impact factor: 13.506

10.  Kin-cohort evaluation of relative risks of genetic variants.

Authors:  Catherine L Saunders; Colin B Begg
Journal:  Genet Epidemiol       Date:  2003-04       Impact factor: 2.135

View more
  10 in total

1.  Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry.

Authors:  Allison W Kurian; Gail D Gong; Esther M John; David A Johnston; Anna Felberg; Dee W West; Alexander Miron; Irene L Andrulis; John L Hopper; Julia A Knight; Hilmi Ozcelik; Gillian S Dite; Carmel Apicella; Melissa C Southey; Alice S Whittemore
Journal:  J Clin Oncol       Date:  2011-10-31       Impact factor: 44.544

2.  Lynch syndrome and cervical cancer.

Authors:  Yoland C Antill; James G Dowty; Aung Ko Win; Tina Thompson; Michael D Walsh; Margaret C Cummings; Steven Gallinger; Noralane M Lindor; Loïc Le Marchand; John L Hopper; Polly A Newcomb; Robert W Haile; James Church; Katherine M Tucker; Daniel D Buchanan; Joanne P Young; Ingrid M Winship; Mark A Jenkins
Journal:  Int J Cancer       Date:  2015-07-14       Impact factor: 7.396

3.  Estimating risks for variants of unknown significance according to their predicted pathogenicity classes with application to BRCA1.

Authors:  J G Dowty; E Lee; R McKean-Cowdin; B E Henderson; L Bernstein; G Ursin; J L Hopper
Journal:  Breast Cancer Res Treat       Date:  2014-01-31       Impact factor: 4.872

4.  Cancer risks for MLH1 and MSH2 mutation carriers.

Authors:  James G Dowty; Aung K Win; Daniel D Buchanan; Noralane M Lindor; Finlay A Macrae; Mark Clendenning; Yoland C Antill; Stephen N Thibodeau; Graham Casey; Steve Gallinger; Loic Le Marchand; Polly A Newcomb; Robert W Haile; Graeme P Young; Paul A James; Graham G Giles; Shanaka R Gunawardena; Barbara A Leggett; Michael Gattas; Alex Boussioutas; Dennis J Ahnen; John A Baron; Susan Parry; Jack Goldblatt; Joanne P Young; John L Hopper; Mark A Jenkins
Journal:  Hum Mutat       Date:  2013-03       Impact factor: 4.878

5.  Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome.

Authors:  Rodrigo Santa Cruz Guindalini; Aung Ko Win; Cassandra Gulden; Noralane M Lindor; Polly A Newcomb; Robert W Haile; Victoria Raymond; Elena Stoffel; Michael Hall; Xavier Llor; Chinedu I Ukaegbu; Ilana Solomon; Jeffrey Weitzel; Matthew Kalady; Amie Blanco; Jonathan Terdiman; Gladis A Shuttlesworth; Patrick M Lynch; Heather Hampel; Henry T Lynch; Mark A Jenkins; Olufunmilayo I Olopade; Sonia S Kupfer
Journal:  Gastroenterology       Date:  2015-08-03       Impact factor: 22.682

6.  Do the risks of Lynch syndrome-related cancers depend on the parent of origin of the mutation?

Authors:  Shimelis Dejene Gemechu; Christine M van Vliet; Aung Ko Win; Jane C Figueiredo; Loic Le Marchand; Steven Gallinger; Polly A Newcomb; John L Hopper; Noralane M Lindor; Mark A Jenkins; James G Dowty
Journal:  Fam Cancer       Date:  2020-02-27       Impact factor: 2.446

7.  Population-based estimate of prostate cancer risk for carriers of the HOXB13 missense mutation G84E.

Authors:  Robert J MacInnis; Gianluca Severi; Laura Baglietto; James G Dowty; Mark A Jenkins; Melissa C Southey; John L Hopper; Graham G Giles
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

8.  Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH.

Authors:  Aung Ko Win; Jeanette C Reece; James G Dowty; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Melissa C Southey; Joanne P Young; Sean P Cleary; Hyeja Kim; Michelle Cotterchio; Finlay A Macrae; Katherine M Tucker; John A Baron; Terrilea Burnett; Loïc Le Marchand; Graham Casey; Robert W Haile; Polly A Newcomb; Stephen N Thibodeau; John L Hopper; Steven Gallinger; Ingrid M Winship; Noralane M Lindor; Mark A Jenkins
Journal:  Int J Cancer       Date:  2016-06-02       Impact factor: 7.316

9.  Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study.

Authors: 
Journal:  Lancet Oncol       Date:  2021-06-07       Impact factor: 54.433

10.  Estimating the age at onset distribution of the asymptomatic stage of a genetic disease based on pedigree data.

Authors:  Marianne A Jonker; Priya Vart; Mar Rodriguez Girondo
Journal:  Stat Methods Med Res       Date:  2019-12-27       Impact factor: 3.021

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.